DE3778281D1 - Immunreagenzien mit erhoehter affinitaet zum nachweis und zur zerstoerung von spezifischen targetzellen. - Google Patents
Immunreagenzien mit erhoehter affinitaet zum nachweis und zur zerstoerung von spezifischen targetzellen.Info
- Publication number
- DE3778281D1 DE3778281D1 DE8787430031T DE3778281T DE3778281D1 DE 3778281 D1 DE3778281 D1 DE 3778281D1 DE 8787430031 T DE8787430031 T DE 8787430031T DE 3778281 T DE3778281 T DE 3778281T DE 3778281 D1 DE3778281 D1 DE 3778281D1
- Authority
- DE
- Germany
- Prior art keywords
- target cells
- reagents
- synthetic
- detecting
- specific target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8613146A FR2604092B1 (fr) | 1986-09-19 | 1986-09-19 | Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3778281D1 true DE3778281D1 (de) | 1992-05-21 |
Family
ID=9339117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8787430031T Expired - Lifetime DE3778281D1 (de) | 1986-09-19 | 1987-09-16 | Immunreagenzien mit erhoehter affinitaet zum nachweis und zur zerstoerung von spezifischen targetzellen. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5256395A (de) |
EP (1) | EP0263046B1 (de) |
JP (1) | JP2612454B2 (de) |
KR (1) | KR900005622B1 (de) |
AT (1) | ATE74769T1 (de) |
AU (1) | AU613318B2 (de) |
CA (1) | CA1306414C (de) |
DE (1) | DE3778281D1 (de) |
ES (1) | ES2032468T3 (de) |
FR (1) | FR2604092B1 (de) |
GR (1) | GR3004914T3 (de) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6416738B1 (en) | 1973-12-07 | 2002-07-09 | Neorx Corporation | Pretargeting methods and compounds |
US6075010A (en) * | 1992-06-09 | 2000-06-13 | Neorx Corporation | Small molecular weight ligand-hexose containing clearing agents |
US5053226A (en) * | 1987-07-15 | 1991-10-01 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
AU609939B2 (en) * | 1988-02-03 | 1991-05-09 | University Of Melbourne, The | Tumour imaging |
CA1339775C (en) * | 1988-06-10 | 1998-03-24 | Shuzo Matsushita | Antibody 0.5b to hiv-i gp 120 modified with toxic substance |
US5439665A (en) * | 1988-07-29 | 1995-08-08 | Immunomedics | Detection and treatment of infectious and inflammatory lesions |
WO1990012109A1 (en) * | 1989-03-30 | 1990-10-18 | Board Of Regents, The University Of Texas System | Monoclonal antibodies binding platinum complexes |
FR2652004B1 (fr) * | 1989-09-21 | 1994-10-28 | Immunotech Partners | Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques. |
US5273743A (en) * | 1990-03-09 | 1993-12-28 | Hybritech Incorporated | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
US5684137A (en) * | 1990-09-28 | 1997-11-04 | Neorx Corporation | S3 N chelating compounds for the radiolabeling of ligands, anti-ligands or other proteins |
US6685930B1 (en) * | 1991-03-27 | 2004-02-03 | Tanox, Inc. | Methods and substances for recruiting therapeutic agents to solid tumors |
US5364612A (en) * | 1991-05-06 | 1994-11-15 | Immunomedics, Inc. | Detection of cardiovascular lesions |
US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
US6358490B2 (en) | 1992-06-09 | 2002-03-19 | Neorx Corporation | Three-step pretargeting methods and compounds |
US5976535A (en) * | 1992-06-09 | 1999-11-02 | Neorx Corporation | Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore |
US5911969A (en) | 1992-06-09 | 1999-06-15 | Neorx Corporation | Pretargeting protocols for enhanced localization of active agents to target sites |
US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
US5624896A (en) * | 1992-06-09 | 1997-04-29 | Neorx Corporation | Clearing agents useful in pretargeting methods |
US5541287A (en) * | 1992-06-09 | 1996-07-30 | Neorx Corporation | Pretargeting methods and compounds |
US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
US6022966A (en) * | 1993-11-22 | 2000-02-08 | Neorx Corporation | Pretargeting methods and compounds |
CA2134239C (en) * | 1992-06-09 | 2004-11-23 | Donald B. Axworthy | Pretargeting methods and compounds |
US6228362B1 (en) | 1992-08-21 | 2001-05-08 | Immunomedics, Inc. | Boron neutron capture therapy using pre-targeting methods |
GB2289679B (en) * | 1993-01-15 | 1997-02-05 | Imp Cancer Res Tech | Compounds comprising a target cell-specific portion and a portion which has DNA endonucleolytic activity, and uses thereof |
GB9300686D0 (en) * | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
DE69420581T2 (de) * | 1993-12-03 | 2000-01-20 | Bracco Spa | Paramagnetische chelate für magnetische kernresonant-diagnose |
US5561043A (en) * | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
DE19500665A1 (de) * | 1995-01-12 | 1996-07-18 | Axel Prof Dr Haase | Verfahren zur ortsauflösenden Abbildung eines Bereiches eines biologischen Objektes mit Hilfe elektromagnetischer Strahlen unter Applikation von Kontrastmittel |
US5955605A (en) * | 1995-02-21 | 1999-09-21 | Neorx Corporation | Biotinidase resistant biotin-DOTA conjugates |
US6770261B2 (en) * | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US6713045B1 (en) | 1995-06-02 | 2004-03-30 | Research Corporation Technologies, Inc. | Targeted magnetic resonance imaging agents for the detection of physiological processes |
US7011812B1 (en) * | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US5900228A (en) | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
US6713046B1 (en) * | 1997-10-27 | 2004-03-30 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
EP1032430A2 (de) | 1997-11-17 | 2000-09-06 | Research Corporation Technologies, Inc. | Mri-mittel zum nachweis von physiologischen mitteln |
US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US7833528B2 (en) * | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
US7052872B1 (en) | 1999-06-22 | 2006-05-30 | Immunomedics, Inc. | Bi-specific antibodies for pre-targeting diagnosis and therapy |
US20040166115A1 (en) * | 2002-11-15 | 2004-08-26 | Immunomedics, Inc. | Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
WO1999066951A2 (en) * | 1998-06-22 | 1999-12-29 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US7387772B1 (en) | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
US6361774B1 (en) * | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
US6576155B1 (en) * | 1998-11-10 | 2003-06-10 | Biocrystal, Ltd. | Fluorescent ink compositions comprising functionalized fluorescent nanocrystals |
US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
AU2001272017A1 (en) * | 2000-06-20 | 2002-01-02 | Immunomedics Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
AU2001276956A1 (en) | 2000-07-17 | 2002-01-30 | California Institute Of Technology | Macrocyclic mri contrast agents |
US7029655B2 (en) | 2000-10-04 | 2006-04-18 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
US20030004236A1 (en) * | 2001-04-20 | 2003-01-02 | Meade Thomas J. | Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances |
US20030135108A1 (en) * | 2001-05-02 | 2003-07-17 | Silva Robin M. | High throughput screening methods using magnetic resonance imaging agents |
US20020197648A1 (en) * | 2001-05-02 | 2002-12-26 | Silva Robin M. | High throughput screening methods using magnetic resonance imaging agents |
US20030033616A1 (en) * | 2001-07-30 | 2003-02-13 | Star-Lack Joshua Morris | Imaging marker transgenes |
RU2004114878A (ru) * | 2001-10-15 | 2005-04-20 | Иммуномедикс, Инк. (Us) | Агенты, увеличивающие аффинность |
WO2003048207A2 (en) * | 2001-11-28 | 2003-06-12 | Immunomedics, Inc. | Anti-dota antibody |
EP1468097A4 (de) * | 2001-12-26 | 2006-01-11 | Immunomedics Inc | Verfahren zur erzeugung mehrwertiger reagentien mit mehrfachspezifität aus v sb h /sb- und v sb l /sb-domänen |
US7011816B2 (en) | 2001-12-26 | 2006-03-14 | Immunomedics, Inc. | Labeling targeting agents with gallium-68 and gallium-67 |
EP1487879B1 (de) * | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Punktmutationen bei bispezifischen antikörpern zur verbesserung der clearance-rate |
EP2287201B1 (de) | 2002-03-01 | 2018-12-12 | Immunomedics, Inc. | RS7-Antikörper |
US20030198597A1 (en) * | 2002-04-22 | 2003-10-23 | Meade Thomas J. | Novel macrocyclic activatible magnetic resonance imaging contrast agents |
AU2003241024A1 (en) * | 2002-05-29 | 2003-12-19 | Immunomedics, Inc. | Methods and compositions for radioimmunotherapy of brain and cns tumors |
US6911083B2 (en) * | 2002-06-11 | 2005-06-28 | Tokyo Institute Of Technology | Method for producing powders made of gallium nitride and apparatus for producing the same |
CN1675245B (zh) | 2002-06-14 | 2011-01-12 | 免疫医疗公司 | 人源化单克隆抗体hPAM4 |
US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
US7993626B2 (en) | 2007-01-11 | 2011-08-09 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
JP3931818B2 (ja) * | 2003-02-13 | 2007-06-20 | 株式会社デンソー | 車両用空調装置 |
CA2522819A1 (en) * | 2003-04-22 | 2004-11-04 | Immunomedics, Inc. | Polyvalent protein complex |
WO2005021494A2 (en) | 2003-06-13 | 2005-03-10 | Immunomedics, Inc. | D-amino acid peptides |
WO2005004809A2 (en) * | 2003-07-01 | 2005-01-20 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
EP1651663B1 (de) * | 2003-08-08 | 2017-05-17 | Immunomedics, Inc. | Bispezifische antikörper zur induktion der apoptose in tumorzellen und erkrankten zellen |
WO2005026325A2 (en) * | 2003-09-10 | 2005-03-24 | Surromed, Inc, | Bivalent targeting of cell surfaces |
EP1602928A1 (de) * | 2004-06-01 | 2005-12-07 | Universiteit Maastricht | Verfahren und Kit zur Bestimmung der Bindungsparameter von Bioaffinitätsbindungsreaktionen |
EP2412728B1 (de) | 2004-08-03 | 2015-01-07 | Innate Pharma | Therapeutische Zusammensetzungen Targeting von 4IG-B7-H3 exprimierenden Tumoren |
EP1831258B2 (de) | 2004-12-28 | 2023-06-07 | Innate Pharma S.A. | Monoklonale antikörper gegen nkg2a |
AU2006218454B2 (en) | 2005-03-03 | 2011-11-17 | Immunomedics, Inc. | Humanized L243 antibodies |
CA2623109C (en) | 2005-10-14 | 2019-02-19 | Innate Pharma | Nk cell-depleting antibodies for treating immunoproliferative disorders |
EP2674440B1 (de) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Polyvalente bioaktive anordnungen auf immunglobulinbasis |
ES2363891T3 (es) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer. |
US8709382B2 (en) | 2007-01-11 | 2014-04-29 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
US8545809B2 (en) | 2007-01-11 | 2013-10-01 | Immunomedics, Inc. | Methods and compositions for improved 18F labeling of proteins, peptides and other molecules |
US8153100B2 (en) * | 2007-01-11 | 2012-04-10 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
US8889100B2 (en) | 2007-01-11 | 2014-11-18 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
ES2712732T3 (es) | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
IN2012DN01663A (de) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
EP3135302A1 (de) | 2009-12-02 | 2017-03-01 | Imaginab, Inc. | J591-minikörper und cys-diakörper zur adressierung des prostataspezifischen membranantigens (psma) und verfahren zu deren verwendung |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
IN2012DN03177A (de) | 2009-12-04 | 2015-09-25 | Immunomedics Inc | |
CA2831572C (en) | 2011-05-02 | 2019-11-26 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
US9139649B2 (en) | 2014-02-25 | 2015-09-22 | Immunomedics, Inc. | Humanized anti-CD22 antibody |
PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
SG11201704175WA (en) * | 2014-11-26 | 2017-06-29 | Baofa Yu | Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
CN107614514B (zh) | 2015-05-20 | 2022-03-01 | 国立大学法人鹿儿岛大学 | 利用IgG结合肽的抗体特异性修饰 |
SG10201913625XA (en) | 2015-08-07 | 2020-03-30 | Imaginab Inc | Antigen binding constructs to target molecules |
US10634680B2 (en) | 2016-04-26 | 2020-04-28 | University Of Utah Research Foundation | Target-binding activated split reporter systems for analyte detection and related components and methods |
KR20230027320A (ko) * | 2016-06-13 | 2023-02-27 | 가고시마 유니버시티 | IgG 결합 펩타이드에 의한 부위 특이적 RI 표지 항체 |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3927193A (en) * | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
US4401764A (en) * | 1980-02-07 | 1983-08-30 | Technicon Instruments Corporation | Immunoassays employing labeled reagent and a conjugate having two binding sites |
DE3173342D1 (en) * | 1980-03-03 | 1986-02-13 | Milton David Goldenberg | Agent for tumor localization and therapy with labeled antibodies and antibody fragments |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
JPS579724A (en) * | 1980-05-21 | 1982-01-19 | Teijin Ltd | Reactive polymer containing bonded cytotoxic substance and its preparation |
US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4433059A (en) * | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
DE3239410A1 (de) * | 1981-10-27 | 1983-05-19 | Hybritech Inc., 92121 San Diego, Calif. | Monoklonale antikoerper zu tumorassoziiertem antigen, zusammensetzungen, welche diese enthalten und deren anwendung zum tumornachweis |
US4445421A (en) * | 1981-11-06 | 1984-05-01 | The Charles Stark Draper Laboratory, Inc. | Helicopter swashplate controller |
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
ES8504461A1 (es) * | 1982-04-12 | 1985-04-16 | Hybritech Inc | Un procedimiento para obtener un polidoma. |
US4470925A (en) * | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
US4446233A (en) * | 1982-05-05 | 1984-05-01 | E. I. Du Pont De Nemours And Company | Homogeneous immunoassay using covalent hybrid antibodies |
US4472509A (en) * | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4741900A (en) * | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4490473A (en) * | 1983-03-28 | 1984-12-25 | Panab | Labeled antibodies and methods |
US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US4661444A (en) * | 1984-03-29 | 1987-04-28 | Ortho Diagnostic Systems Inc. | Homogeneous immunoassays employing double antibody conjugates comprising anti-idiotype antibody |
JPH0617909B2 (ja) * | 1984-04-23 | 1994-03-09 | ボストン バイオメディカル リサーチ インスティテュート,インコーポレイテッド | 双特異性抗体決定子 |
US4722892A (en) * | 1984-08-31 | 1988-02-02 | Meares Claude F | Monoclonal antibodies against metal chelates |
GB8422452D0 (en) * | 1984-09-05 | 1984-10-10 | Serono Diagnostics Ltd | Assay |
US4760142A (en) * | 1984-11-27 | 1988-07-26 | Hoechst Celanese Corporation | Divalent hapten derivatives |
CA1282069C (en) * | 1985-09-12 | 1991-03-26 | Damon L. Meyer | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4863713A (en) * | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
-
1986
- 1986-09-19 FR FR8613146A patent/FR2604092B1/fr not_active Expired - Lifetime
-
1987
- 1987-09-10 US US07/096,829 patent/US5256395A/en not_active Expired - Lifetime
- 1987-09-16 DE DE8787430031T patent/DE3778281D1/de not_active Expired - Lifetime
- 1987-09-16 AT AT87430031T patent/ATE74769T1/de not_active IP Right Cessation
- 1987-09-16 EP EP87430031A patent/EP0263046B1/de not_active Expired - Lifetime
- 1987-09-16 ES ES198787430031T patent/ES2032468T3/es not_active Expired - Lifetime
- 1987-09-17 CA CA000547184A patent/CA1306414C/en not_active Expired - Lifetime
- 1987-09-18 AU AU78656/87A patent/AU613318B2/en not_active Ceased
- 1987-09-18 JP JP62234680A patent/JP2612454B2/ja not_active Expired - Lifetime
- 1987-09-18 KR KR1019870010382A patent/KR900005622B1/ko not_active IP Right Cessation
-
1992
- 1992-06-11 GR GR920401264T patent/GR3004914T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA1306414C (en) | 1992-08-18 |
ES2032468T3 (es) | 1993-02-16 |
FR2604092A1 (fr) | 1988-03-25 |
JP2612454B2 (ja) | 1997-05-21 |
ATE74769T1 (de) | 1992-05-15 |
FR2604092B1 (fr) | 1990-04-13 |
AU7865687A (en) | 1988-04-21 |
KR880004312A (ko) | 1988-06-07 |
JPS63159327A (ja) | 1988-07-02 |
EP0263046A1 (de) | 1988-04-06 |
EP0263046B1 (de) | 1992-04-15 |
KR900005622B1 (ko) | 1990-07-31 |
GR3004914T3 (de) | 1993-04-28 |
AU613318B2 (en) | 1991-08-01 |
US5256395A (en) | 1993-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3778281D1 (de) | Immunreagenzien mit erhoehter affinitaet zum nachweis und zur zerstoerung von spezifischen targetzellen. | |
NZ217570A (en) | Antibody complexes of hapten modified diagnostic or therapeutic agents | |
ATE120457T1 (de) | Macrocyclische bifunktionelle chelatbildner, komplexe davon und ihre konjugierten antikörper. | |
DE3766157D1 (de) | Kupplungsmittel zum radiomarkieren von proteinen. | |
KR910005862A (ko) | 신규 친수성 유도체, 진단 또는 치료시 그의 응용 그를 함유하는 진단 또는 치료용 키트 및 면역 시약 | |
NO904919D0 (no) | Materiale for diagnotisering og behandling av insulinavhengig diabetes mellitus samt fremstilling av slikt materiale | |
DE3588210D1 (de) | Biologisch nützliche Konjugate | |
FR2319131A1 (fr) | Procede pour detecter et separer les antigenes et les anticorps dans le sang ou autres echantillons | |
ATE382370T1 (de) | Antikörper-serumprotein hybride | |
ATE182007T1 (de) | Bestimmung der kompatibilität anhand von löslichem hla | |
DE69001972T2 (de) | Mittel zum nachweis von gehirnkrankheiten in zusammenhang mit nervenscheidenmarkzerstoerung, insbesondere sklerosis multiplex. | |
DE59410003D1 (de) | Synthetischer Standard für Immunoassays | |
ES2142070T3 (es) | Utilizacion de un complejo ficobiliproteina-peptido de enlace como trazador fluorescente. | |
DE3577630D1 (de) | Vorrichtung zum nachweis von zwei roentgenstrahlenergien. | |
DE3650497D1 (de) | Verfahren und Zusammensetzung zum Nachweis von Analyt-Anteilen | |
DE69231495D1 (de) | Neue cocain-derivate und protein- und polypeptid-cocain-derivate, konjugate und markierte verbindungen | |
DE68908257T2 (de) | Millonreagenz zum Nachweis von Krebs. | |
ATE52251T1 (de) | Histamin-derivate, immunogen-konjugate und dadurch induzierte antikoerper. | |
DE69028561T2 (de) | Immunoassay zum Nachweis von Antikörpern gegen HIV | |
ES501387A0 (es) | Procedimiento de deteccion de la presencia de antigenos de un grupo sanguineo a,b,0 o ab en un corte histologico | |
ATE73463T1 (de) | Monoklonale antikoerper. | |
NO970130D0 (no) | Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener | |
Grannikova et al. | Use of a highly sensitive electrophoresis-precipitation method to detect virus hepatitis B antigen in human blood serum | |
ATE17190T1 (de) | Mittel zur tumorlokalisierung und therapie mit markierten antikoerpern und antikoerperfragmenten. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |